Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | DUT | P33316 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543444 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL1879256 | 0.80 | DUT (0.65) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL1879258 | 0.80 | DUT (0.65) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL8540687 | 0.79 | DUT (0.64) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL1884831 | 0.78 | DUT (0.58) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL1884832 | 0.78 | DUT (0.58) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL10015801 | 0.77 | DUT (0.54) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL9216504 | 0.76 | DUT (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL3234890 | 0.75 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL8540086 | 0.75 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-0377846-A1 | Pharmaceutical mixture preparation containing nucleoside derivatives and pentosan polysulfate, and its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-07-18 | — | — | EP | claimed |
| JP-7145058-A | — | — | None | — | — | JP | disclosed |
| JP-5097847-A | — | — | None | — | — | JP | disclosed |
| JP-4077485-A | — | — | None | — | — | JP | disclosed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| US-4962193-A | ADSORPTION ON POROUS NON-POLAR RESIN, THEN SEPARATION AND ELUTION | AJINOMOTO CO., INC. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0377846-A1 | Pharmaceutical mixture preparation containing nucleoside derivatives and pentosan polysulfate, and its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-07-18 | — | — | EP | disclosed |
| US-4904770-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS COMPANY (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0334368-A2 | Production of 2',3'-dideoxy-2',3'-Didehydronucleosides | Bristol-Myers Squibb Company (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4835104-A | Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides | AJINOMOTO CO., INC., PATENT & LICENSING DEPARTMENT (JP) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ALDH1A1 2112/4885LMNA 3677/4885ALB 4137/4885 |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | ALDH1A1 3548/4885LMNA 1280/4885ALB 3076/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | ALDH1A1 2758/4885LMNA 1661/4885ALB 3481/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ALDH1A1 2112/4885LMNA 3677/4885ALB 4137/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | ALDH1A1 2739/4885LMNA 2736/4885ALB 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.